Key facts
- Jetbio’s last known valuation is $940K (Jan 2025).
- It has raised $680K; the latest was Seed Round ($680K) in Jan 2025.
- Notable investors include Newcastle University.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Jetbio
- ·The full record, as it builds
Funding rounds
No funding rounds for Jetbio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Jetbio
Developer of a 3D bioprinting technology designed to support drug discovery and regenerative medicine. The company offers validated bio-inkjet systems and the ability to print biomimetic, cell-filled gels that replicate human tissue, enabling pharmaceutical companies and biomedical researchers to accelerate drug testing, improve disease modeling, and reduce development time and cost.
- Sector
- Healthcare
- HQ
- Newcastle upon Tyne, United Kingdom
- Founded
- 2023
- Employees
- 3
- Website
- jet-bio.com/
- Ownership
- Privately Held (backing)
Jetbio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Jetbio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Jetbio in its N-PORT filings yet. We sweep new filings monthly.